Literature DB >> 2055022

Systemic chemotherapy for ocular cicatricial pemphigoid.

J Tauber1, M Sainz de la Maza, C S Foster.   

Abstract

The records of 105 patients treated with three different chemotherapeutic agents for ocular cicatricial pemphigoid (OCP) were reviewed to compare long-term efficacies, side effects, and tolerance of different regimens. For the entire group, OCP progressed in 6% of eyes in 10% of patients (follow-up 35 months). More than half of the treatment failures occurred in patients intolerant of chemotherapy. Diaminodiphenylsulfone (DAP), as initial agent, failed to control disease in 2% of patients, compared with 8% after cyclophosphamide (CYC) and 9% after azathioprine (AZA) (p less than 0.05). Stratification of results revealed that DAP was the most effective initial agent for modestly active OCP, whereas CYC was the most effective initial choice for highly active cases. In patients treated with a single agent exclusively for 10 months or more, failure to control disease occurred in 4% of DAP, 4% of CYC, and 15% of AZA patients (p less than 0.01). Recommendations for a sequential approach to chemotherapy for OCP are presented.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2055022     DOI: 10.1097/00003226-199105000-00001

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  16 in total

1.  Dapsone induced haemolytic anaemia in patients treated for ocular cicatricial pemphigoid.

Authors:  M S Wertheim; J J Males; S D Cook; D M Tole
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

2.  Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid.

Authors:  C S Foster; R Neumann; J Tauber
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

3.  Eosinophil granule proteins expressed in ocular cicatricial pemphigoid.

Authors:  A Heiligenhaus; J Schaller; S Mauss; S Engelbrecht; J E Dutt; C S Foster; K P Steuhl
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

Review 4.  Ocular mucous membrane pemphigoid: a review.

Authors:  Samanta Taurone; Marialuisa Spoletini; Massimo Ralli; Pietro Gobbi; Marco Artico; Laszlò Imre; Cecília Czakò; Illés Kovàcs; Antonio Greco; Alessandra Micera
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

5.  Incidence, clinical features and diagnosis of cicatrising conjunctivitis in Australia and New Zealand.

Authors:  Samantha Bobba; Connor Devlin; Nick Di Girolamo; Denis Wakefield; Peter McCluskey; Elsie Chan; Mark Daniell; Stephanie Watson
Journal:  Eye (Lond)       Date:  2018-06-19       Impact factor: 3.775

Review 6.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

7.  Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid.

Authors:  M J Elder; J Leonard; J K Dart
Journal:  Br J Ophthalmol       Date:  1996-06       Impact factor: 4.638

8.  Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid.

Authors:  M J Elder; S Lightman; J K Dart
Journal:  Br J Ophthalmol       Date:  1995-03       Impact factor: 4.638

Review 9.  Mucous membrane pemphigoid.

Authors:  Hong-Hui Xu; Victoria P Werth; Ernesta Parisi; Thomas P Sollecito
Journal:  Dent Clin North Am       Date:  2013-08-15

Review 10.  [Mucous membrane pemphigoid with ocular involvement. Part II: therapy].

Authors:  T Meyer-ter-Vehn; E Schmidt; D Zillikens; G Geerling
Journal:  Ophthalmologe       Date:  2008-04       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.